Anti-vWf antibodies induce GPIbα and FcγRII mediated platelet aggregation only at low shear forces

被引：5

作者：

Hoylaerts M.F. ^{[1
]}

Viaene A. ^{[2
]}

Thys C. ^{[1
]}

Deckmyn H. ^{[2
]}

Vermylen J. ^{[1
]}

机构：

[1] Center for Molecular and Vascular Biology, University of Leuven, KU Leuven

[2] Laboratory for Thrombosis Research, Interdisciplinary Research Center, KU Leuven Campus, Kortrijk

来源：

Journal of Thrombosis and Thrombolysis | 2001年 / 12卷 / 3期

关键词：

GPIb; Phage display; Platelet aggregation; Synergism; Von Willebrand factor;

D O I：

10.1023/A:1015279109247

中图分类号：

学科分类号：

摘要：

Background/methods: Anti-von Willebrand factor (vWf) antibody mediated platelet activation was studied using 2 monoclonal anti-vWf antibodies promoting the binding of vWf to GPIbα: 1C1E7 (IgG2a) reacting with the vWf N-terminus and 75H4B12 (IgM), characterized in this paper and studied in association with 1C1E7. Results: 75H4B12 binds to an N-terminal epitope in vWf, different from that reacting with 1C1E7. When combined, 1C1E7 and 75H4B12 promoted vWf binding to isolated GPIb under static conditions, even in the absence of ristocetin or botrocetin, and induced platelet aggregation synergistically in the presence of zero to subthreshold ristocetin concentrations. Specific inhibitors of GPIbα-vWf interactions prevented vWf binding to GPIbα in ELISA and during platelet aggregation. In addition, the 1C1E7 dependent platelet aggregation involved Fc receptor mediated platelet activation, a phenomenon even more pronounced when 1C1E7 and 75H4B12 were combined. A 75H4B12 binding phage expressing a peptide homologous with vWf sequence 88-95 neutralized the antibody induced platelet activation. However, at arterial shear rates, both 1C1E7 and 75H4B12 potently prolonged cartridge closure times in the PFA-100, compatible with inhibition of platelets by vWf, unfolded by the combined action of shear stress and antibodies. Conclusions: We conclude that antibodies directed against different epitopes in the N-terminus of vWf modify the folded vWf structure synergistically and enhance A1 domain mediated vWf binding to platelet GPIb at low shear forces. In addition, once platelet-bound, IgG antibodies potently activate platelets via the FcγII receptor. Thus, such antibodies may promote immune mediated thrombosis at low shear rates, typical of the venous circulation. In contrast, at arterial shear rates, anti-vWf antibodies may rather compromise platelet function following enhanced binding of the unfolded vWf multimers to platelets, shielding platelets from interacting with subendothelial and soluble ligands.

引用

页码：249 / 262

页数：13

共 46 条

[1]

Vermylen J., Hoylaerts M.F., Arnout J., Antibody-mediated thrombosis, Thromb Haemost, 78, pp. 420-426, (1997)

[2]

Takeya H., Mori T., Gabazza E.C., Kuroda K., Deguchi H., Matsuura E., Ichikawa K., Koike T., Suzuki K., Antibeta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids, J Clin Invest, 99, pp. 2260-2268, (1997)

[3]

Arvieux J., Roussel B., Pouzol P., Colomb M.G., Platelet activating properties of murine monoclonal antibodies to beta 2-glycoprotein I, Thromb Haemost, 70, pp. 336-341, (1993)

[4]

Arnout J., Wittevrongel C., Vanrusselt M., Hoylaerts M., Vermylen J., Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody beta-2-glycoprotein I complexes on phospholipid surfaces, Thromb Haemost, 79, pp. 79-86, (1998)

[5]

Kelton J.G., Heparin-induced thrombocytopenia, Haemostasis, 16, pp. 173-186, (1986)

[6]

Kelton J.G., Smith J.W., Warkentin T.E., Hayward C.P., Denomme G.A., Horsewood P., Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4, Blood, 83, pp. 3232-3239, (1994)

[7]

Warkentin T.E., Chong B.H., Greinacher A., Heparin-induced thrombocytopenia: Towards consensus, Thromb Haemost, 79, pp. 1-7, (1998)

[8]

Rinder M.R., Richard R.E., Rinder H.M., Acquired von Willebrand's disease: A concise review, Am J Hematol, 54, pp. 139-145, (1997)

[9]

Veyradier A., Jenkins C.S.P., Fressinaud E., Meyer D., Acquired von Willebrand Syndrome: From pathophysiology to management, Thromb Haemost, 84, pp. 175-182, (2000)

[10]

Hoylaerts M.F., Thys C., Arnout J., Vermylen J., Autoimmune anti-von Willebrand factor antibodies induce FcγRII receptor mediated platelet activation and thrombosis, Blood, 91, pp. 2810-2817, (1998)

← 1 2 3 4 5 →